How to Keep Muscle While Taking Ozempic, Wegovy, or Mounjaro

The Muscle Loss Problem

The GLP-1 class of medications has been one of the most effective weight-loss pharmaceuticals in medical history. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) produce weight loss in the range of 15 to 22% of baseline bodyweight over 68 weeks. The results on the scale are unlike anything that came before.

The results on body composition are a different story. When researchers used DEXA scanning to measure exactly what kind of weight was being lost, the picture got more complicated.

In the STEP 1 trial (the pivotal study for semaglutide), participants lost an average of 15.3 kg of total body weight over 68 weeks. A body composition substudy published in Diabetes, Obesity and Metabolism found that approximately 39% of that total weight loss was lean body mass. Similar patterns showed up in the SURMOUNT-1 trial of tirzepatide and across smaller independent studies.

Wilding JPH et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," N Engl J Med, 2021. Body composition substudy: Wilding JPH et al., "Weight regain and cardiometabolic effects after withdrawal of semaglutide," Diabetes Obes Metab, 2022. View study

For reference, surgical weight loss (gastric bypass or sleeve gastrectomy) typically drives about 20 to 25% lean mass loss. Traditional calorie-restriction diets with resistance training lose 10 to 20%. GLP-1s without intervention lose substantially more lean mass as a percentage of total weight lost than almost any other approach.

Why GLP-1s Hit Muscle Disproportionately

The mechanism is not primarily pharmacological. GLP-1 receptor agonists do not appear to directly degrade muscle tissue in any meaningful way. The muscle loss is a downstream consequence of how these drugs work.

Appetite suppression reduces protein intake

The defining clinical effect of a GLP-1 is profound appetite suppression. Patients eat 20 to 35% fewer calories by preference, not by rule. Protein intake tends to drop proportionally or worse, because protein is satiating and feels harder to finish when you're already not hungry. Multiple dietary studies of GLP-1 users find average protein intake well below 0.6 g/kg bodyweight, which is roughly half of what's needed to preserve muscle in a caloric deficit.

Rapid caloric deficit accelerates catabolism

When weight loss exceeds about 1% of bodyweight per week, the body shifts into a more catabolic state. It breaks down both fat and muscle for energy. GLP-1 users often lose weight faster than this threshold, especially in the first 12 to 16 weeks of therapy. The body doesn't distinguish between the fat you want to lose and the muscle you don't.

Fatigue reduces the training stimulus

The gastrointestinal side effects and early-phase fatigue common on GLP-1s reduce training frequency and intensity. Muscle requires mechanical load to be retained. A patient who was lifting three times per week before starting semaglutide and drops to once a week during the titration phase has effectively removed the primary signal that tells the body to keep muscle tissue.

Age is a multiplier

Sarcopenia (age-related muscle loss) progresses at around 1% per year after age 30, accelerating to 1.5-2% per year after 60. A 55-year-old starting a GLP-1 is already in negative muscle balance before the drug enters the picture. The combination of age-related sarcopenia and GLP-1 catabolism can produce dramatic lean mass losses in 6 to 12 months.

The Non-Negotiable Foundation

No peptide can overcome a protein deficit or a complete absence of training stimulus. Before considering any pharmacological support for muscle preservation, two things have to be in place.

Protein intake of 1.0 to 1.2 grams per pound of goal bodyweight. For a 160-pound goal weight, that's 160 to 192 grams of protein per day. This is higher than most general nutrition advice because weight-loss phases require higher protein to preserve muscle. If appetite suppression makes food volume difficult, protein shakes, Greek yogurt, cottage cheese, and lean meats deliver the most protein per bite.

Resistance training three or more times per week. Compound movements (squats, deadlifts, presses, rows) drive the largest training signal and are more time-efficient than isolation work. The goal is not to build new muscle during a deficit. The goal is to send the body the message that the existing muscle is being used and should be retained. Training volume matters less than consistency.

Patients who get both of these dialed in preserve substantially more muscle on GLP-1s than patients who don't, even without any additional pharmacological support. A 2023 study on resistance training during semaglutide therapy found that trained patients retained nearly twice as much lean mass compared to sedentary peers on identical doses.

Where Peptides Fit In

Even with optimal protein intake and consistent training, the caloric deficit itself creates a headwind. Growth hormone and its downstream mediator IGF-1 are the body's two most important signals for muscle preservation. Both decline in a deficit. Both decline further with age. A GLP-1 user in their 40s or 50s is often running low on these signals at exactly the moment their body needs them most.

Growth hormone axis peptides restore part of that signaling. They don't replace protein or training. They extend the effectiveness of both by maintaining the hormonal environment that lets the body respond to those inputs.

The Peptide Options

Sermorelin

Sermorelin is a 29-amino-acid fragment of growth hormone releasing hormone (GHRH). It prompts the pituitary to release its own growth hormone in the natural pulsatile pattern. This is important because natural pulsatile GH release avoids the downsides of continuous elevated GH (insulin resistance, swelling, carpal tunnel) that come with synthetic HGH.

Sermorelin is the gentlest of the GH-axis peptides. It's well-tolerated, has the longest clinical track record (originally FDA-approved in 1997 for pediatric growth hormone deficiency), and is a reasonable starting point for patients new to peptide therapy. Expect moderate improvements in sleep quality, recovery, and lean mass preservation within 8 to 12 weeks.

The gentlest of the GH-axis peptides.

Shop Now

CJC-1295 / Ipamorelin

CJC-1295 is a modified GHRH analog with a longer half-life than Sermorelin. Ipamorelin is a selective growth hormone secretagogue that binds a different receptor (GHSR, the ghrelin receptor). Together they produce a stronger GH pulse than either alone, without meaningfully raising cortisol or prolactin, which is why Ipamorelin is preferred over older GHRPs like GHRP-2 or GHRP-6.

This combination is the most popular choice among patients on a GLP-1 who want a noticeable body composition effect. It preserves more lean mass, drives better sleep quality, and produces a measurable improvement in recovery between training sessions. Dosed subcutaneously before bed to align with the body's natural overnight GH pulse.

The most common choice for body composition during a GLP-1 course.

Shop Now

Tesamorelin / Ipamorelin

Tesamorelin is the most clinically studied GHRH analog for body composition specifically. It is FDA-approved for treatment of HIV-associated lipodystrophy, where it reduced visceral adipose tissue by 15 to 20% in pivotal trials. Combined with Ipamorelin, it delivers both the visceral fat reduction and the lean mass preservation that GLP-1 users commonly need.

This combination is typically recommended for patients with significant visceral fat at baseline or for those who have tried CJC/Ipa without the body composition result they wanted. It's also a common choice for patients who have completed their GLP-1 course and are working on reshaping rather than continued weight loss.

Strongest evidence base for visceral fat reduction.

Shop Now

Falutz J et al., "Effects of Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat," J Clin Endocrinol Metab, 2010. View study

MOTS-c (supporting role)

MOTS-c is a mitochondrial-derived peptide that improves insulin sensitivity and metabolic flexibility. It's not a growth hormone peptide, so it doesn't directly preserve muscle. What it does is support the metabolic environment around weight loss. Better glucose disposal, better mitochondrial function, and better endurance are all downstream of MOTS-c signaling. Some patients add it alongside a GHRH peptide rather than choosing one over the other.

Timing, Duration, and After GLP-1

Most providers recommend starting a GH-axis peptide 2 to 4 weeks after beginning a GLP-1, once the early GI side effects have settled. Starting both at once is harder on the patient because any side effect becomes ambiguous in origin.

Protocols typically run 3 to 6 months, mirroring the initial weight-loss phase of the GLP-1. After that, many patients continue the peptide through the maintenance phase at a lower dose, then cycle off for 2 to 3 months before re-starting. Continuous year-round GH-axis stimulation is not standard practice.

The most important timing decision is what happens when the GLP-1 stops. Patients who discontinue a GLP-1 without continuing muscle-preservation support tend to rebound with fat gain. Running a GH-axis peptide for 3 to 6 months after stopping the GLP-1 reduces this rebound and helps cement the new body composition.

Safety and Medical Oversight

Growth hormone axis peptides are not appropriate for every patient. The primary contraindications are active malignancy, pregnancy, certain pituitary disorders, and severe insulin resistance that could be worsened by elevated GH. Patients with a history of cancer should discuss their specific oncology history with both their oncologist and prescribing provider before starting.

There are no documented pharmacological interactions between GH-axis peptides and GLP-1 receptor agonists. They act on entirely different pathways. However, both classes can affect glucose regulation in different directions, so patients with diabetes should expect closer monitoring of fasting glucose and HbA1c during the first 8 to 12 weeks of dual therapy.

All PeRx protocols are reviewed by a licensed medical provider who accounts for the patient's full medication list, medical history, lab values, and goals. Peptide therapy is not a product you take independently of the rest of your medical care.

Frequently Asked Questions